All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MDS Hub was pleased to speak to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, during the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting. We asked, “What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?”
What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?
Platzbecker discusses the open-label, randomized, controlled, phase III COMMANDS trial (NCT03682536), previously covered by the MDS Hub, which investigated luspatercept versus epoetin alfa for the treatment of anemia in transfusion-dependent, erythropoiesis-stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS). He highlights the association of treatment with luspatercept and improved transfusion independence found in the trial, and discusses the impact of these results on clinical practice.
Subscribe to get the best content related to MDS delivered to your inbox